Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech binary events -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (141)	3/10/2004 2:11:26 PM
From: tuck	Read Replies (2) \| Respond to of 295

>>10:01AM OSIP tgt raised to $43 at BofA Sec 38.02 +0.54: BofA Sec is raising its price target to $43 from $36. Firm notes that results of OSIPs Phase III study of Tarceva in 2nd/3rd line non-small cell lung cancer (NSCLC) are due shortly. Management guidance has been to expect these results in the April/May timeframe. Firm expects the results to be positive, and believes that investors should buy OSIP shares no matter the outcome of the BR.21 NSCLC study. Firm states that even if the trial fails, alternate viable registration options exist in indications such as malignant glioma (brain cancer) or BAC (a form of lung cancer).<< In the context of our last two posts on this subject, could this be setting up OSIP for a stumble? Also, wondering how binary the TOP data for NPSP's PREOS will be. Given that the rat carcinogenicity data looked pretty good, it's hard to imagine it doing worse than Forteo. Odds are it will do better, though perhaps not well enough to avoid a warning about osteosarcoma on the label. Been a while since anybody posted here. Are there other ideas out there? Cheers, Tuck